289 related articles for article (PubMed ID: 22364580)
1. Glucose-lowering treatment and clinical results in 163 121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register.
Ekström N; Miftaraj M; Svensson AM; Andersson Sundell K; Cederholm J; Zethelius B; Gudbjörnsdottir S; Eliasson B
Diabetes Obes Metab; 2012 Aug; 14(8):717-26. PubMed ID: 22364580
[TBL] [Abstract][Full Text] [Related]
2. Associations of HbA1c and educational level with risk of cardiovascular events in 32,871 drug-treated patients with Type 2 diabetes: a cohort study in primary care.
Östgren CJ; Sundström J; Svennblad B; Lohm L; Nilsson PM; Johansson G
Diabet Med; 2013 May; 30(5):e170-7. PubMed ID: 23350893
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
[TBL] [Abstract][Full Text] [Related]
4. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.
Alvarez Guisasola F; Mavros P; Nocea G; Alemao E; Alexander CM; Yin D
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():8-15. PubMed ID: 18435669
[TBL] [Abstract][Full Text] [Related]
5. Characterization of cardiovascular outcomes in a type 2 diabetes glucose supply and insulin demand model.
Monte SV; Schentag JJ; Adelman MH; Paladino JA
J Diabetes Sci Technol; 2010 Mar; 4(2):382-90. PubMed ID: 20307400
[TBL] [Abstract][Full Text] [Related]
6. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
7. Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival.
Currie CJ; Holden SE; Jenkins-Jones S; Morgan CL; Voss B; Rajpathak SN; Alemayehu B; Peters JR; Engel SS
Diabetes Obes Metab; 2018 Apr; 20(4):821-830. PubMed ID: 29119713
[TBL] [Abstract][Full Text] [Related]
8. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.
Anyanwagu U; Mamza J; Mehta R; Donnelly R; Idris I
Heart; 2016 Oct; 102(19):1581-7. PubMed ID: 27217068
[TBL] [Abstract][Full Text] [Related]
10. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study.
Penfornis A; Blicklé JF; Fiquet B; Quéré S; Dejager S
Vasc Health Risk Manag; 2014; 10():341-52. PubMed ID: 24966684
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
[TBL] [Abstract][Full Text] [Related]
12. Treatment Patterns in Patients With Newly Diagnosed Type 2 Diabetes in China: A Retrospective, Longitudinal Database Study.
Wang C; Gao Y; Zhu L; Huang M; Wu Y; Xuan J
Clin Ther; 2019 Aug; 41(8):1440-1452. PubMed ID: 31155146
[TBL] [Abstract][Full Text] [Related]
13. Glucose supply and insulin demand dynamics of antidiabetic agents.
Monte SV; Schentag JJ; Adelman MH; Paladino JA
J Diabetes Sci Technol; 2010 Mar; 4(2):365-81. PubMed ID: 20307399
[TBL] [Abstract][Full Text] [Related]
14. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report.
Abraira C; Duckworth WC; Moritz T;
Diabetes Obes Metab; 2009 Feb; 11(2):150-6. PubMed ID: 18671796
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
[TBL] [Abstract][Full Text] [Related]
16. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.
Palmer SC; Mavridis D; Nicolucci A; Johnson DW; Tonelli M; Craig JC; Maggo J; Gray V; De Berardis G; Ruospo M; Natale P; Saglimbene V; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque L; Lloyd A; Ahmad N; Liu Y; Tiv S; Wiebe N; Strippoli GF
JAMA; 2016 Jul; 316(3):313-24. PubMed ID: 27434443
[TBL] [Abstract][Full Text] [Related]
18. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study.
Kawamori R; Node K; Hanafusa T; Atsumi Y; Naito Y; Oka Y
Cardiovasc Diabetol; 2013 Sep; 12():131. PubMed ID: 24011395
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
Seufert J; Pegelow K; Bramlage P
Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
[TBL] [Abstract][Full Text] [Related]
20. Study rationale and design of the CIMT trial: the Copenhagen Insulin and Metformin Therapy trial.
Lundby Christensen L; Almdal T; Boesgaard T; Breum L; Dunn E; Gade-Rasmussen B; Gluud C; Hedetoft C; Jarloev A; Jensen T; Krarup T; Johansen LB; Lund SS; Madsbad S; Mathiesen E; Moelvig J; Nielsen F; Perrild H; Pedersen O; Roeder M; Sneppen SB; Snorgaard O; Tarnow L; Thorsteinsson B; Vaag A; Vestergaard H; Wetterslev J; Wiinberg N;
Diabetes Obes Metab; 2009 Apr; 11(4):315-22. PubMed ID: 19267709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
